Scientific letterLevosimendan as bridge to transplant in patients with advanced heart failureLevosimendán como terapia puente a trasplante cardiaco en pacientes con insuficiencia cardiaca avanzada
Section snippets
FUNDING
This study was supported by the Instituto de Salud Carlos III and the European Regional Development Fund (ERDF) through the Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV).
CONFLICTS OF INTEREST
Juan F. Delgado has delivered presentations at Orion Pharma conferences and has participated in clinical trials funded by Orion Pharma. Javier de Juan and Inés Ponz have delivered presentations at Orion Pharma conferences.
References (6)
- et al.
Effect of Levosimendan on the short-term clinical course of patients with acutely decompensated heart failure
JACC Heart Fail.
(2013) - et al.
The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update
J Heart Lung Transplant.
(2016) - et al.
XXIX Informe Oficial de la Sección de Insuficiencia Cardiaca de la Sociedad Española de Cardiología (1984-2017)
Rev Esp Cardiol.
(2018)
There are more references available in the full text version of this article.
Cited by (0)
© 2019 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.